CSIMarket
 
Eyepoint Pharmaceuticals Inc   (EYPT)
Other Ticker:  
 
 
Price: $21.4800 $-0.26 -1.196%
Day's High: $22.6 Week Perf: -6.08 %
Day's Low: $ 21.15 30 Day Perf: -25.73 %
Volume (M): 2,823 52 Wk High: $ 30.99
Volume (M$): $ 60,636 52 Wk Avg: $12.46
Open: $21.70 52 Wk Low: $2.21



 Market Capitalization (Millions $) 824
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) 43
 Net Income (TTM) (Millions $) -100
 Cash Flow (TTM) (Millions $) 58
 Capital Exp. (TTM) (Millions $) 3

Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc is a specialty biopharmaceutical company that focuses on developing innovative and sustained-release therapeutics for treating various eye diseases. The company's primary goal is to improve patient outcomes and provide more convenient treatment options for ophthalmic conditions. Eyepoint employs advanced technology to develop unique drug delivery systems that can achieve long-lasting therapeutic effects with a single dose. Their product portfolio includes treatments for conditions such as macular edema, posterior uveitis, and other retinal diseases. Eyepoint Pharmaceuticals aims to transform the treatment landscape for eye diseases and enhance the quality of life for patients.


   Company Address: 480 Pleasant Street Watertown 2472 MA
   Company Phone Number: 926-5000   Stock Exchange / Ticker: NASDAQ EYPT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

EyePoint Pharmaceuticals Empowers New Employees with Inducement Grants, Boosting Growth Potential

Published Fri, Feb 16 2024 12:00 PM UTC



EyePoint Pharmaceuticals, a leading company dedicated to enhancing the lives of patients with retinal diseases, has recently made an exciting announcement regarding inducement grants. By granting non-statutory stock options to new employees outside their existing incentive plan, EyePoint Pharmaceuticals showcases its commitment to fostering talent and driving long-...

Clinical Study

EyePoint Pharmaceuticals Presents Encouraging Subgroup Analysis Results for EYP-1901 in Phase 2 DAVIO 2 Clinical Trial at the Angiogenesis, Exudation, and Degeneration 2024 Meeting

Published Sat, Feb 3 2024 9:20 PM UTC

Sophisticated EyePoint Pharmaceuticals Unveils Promising Subgroup Analysis Results for EYP-1901 in Phase 2 DAVIO 2 Clinical TrialEyePoint Pharmaceuticals, a leading developer and marketer of therapeutic solutions for retinal diseases, has recently released encouraging subgroup analysis findings from their Phase 2 DAVIO 2 clinical study on EYP-1901. This investigational trea...

Shares

EyePoint Pharmaceuticals Bolsters R&D Capabilities with Inducement Grants and Successful Public Offerings, Striving to Transform Treatment for Retinal Diseases

Published Tue, Jan 16 2024 12:00 PM UTC

EyePoint Pharmaceuticals Grants Inducement Stock Options and Successfully Completes Public Offerings to Support Growth in the Treatment of Retinal Diseases
WATERTOWN, Mass., Jan. 16, 2024 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company dedicated to enhancing the lives of patients suffering from severe retinal diseases, announced today that it...

Clinical Study

Advancing Therapeutic Frontiers: EyePoint Pharmaceuticals Commences Phase 2 VERONA Clinical Trial for DME Treatment with Novel EYP-1901

Published Wed, Jan 10 2024 12:00 PM UTC

Innovative Therapeutic Approaches: EyePoint Pharmaceuticals Launches Phase 2 VERONA Clinical Trial for DME Treatment with EYP-1901In the domain of ophthalmic therapeutics, EyePoint Pharmaceuticals, Inc., a prominent player committed to enhancing health outcomes for patients with serious retinal diseases, makes another gallant stride. The initial patient, in the innovative Ph...

Shares

EyePoint Pharmaceuticals Raises $230 Million in Upsized Public Offering, Fueling Breakthroughs in Retinal Disease Treatment

Published Fri, Dec 8 2023 9:01 PM UTC

EyePoint Pharmaceuticals, a leading company focused on developing and commercializing therapeutics for serious retinal diseases, has announced the successful closure of its underwritten public offering. The offering consisted of 13,529,411 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 1,764,705 shares. Priced at $17...






 

Eyepoint Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com